Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Accounts Receivables
Mayne Pharma Group Ltd
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Accounts Receivables
AU$177.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accounts Receivables
AU$18.6m
|
CAGR 3-Years
191%
|
CAGR 5-Years
82%
|
CAGR 10-Years
27%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Accounts Receivables
AU$219.6k
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
Probiotec Ltd
ASX:PBP
|
Accounts Receivables
AU$34.7m
|
CAGR 3-Years
40%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Vita Life Sciences Ltd
ASX:VLS
|
Accounts Receivables
AU$11.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
See Also
What is Mayne Pharma Group Ltd's Accounts Receivables?
Accounts Receivables
177.4m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Accounts Receivables amounts to 177.4m AUD.
What is Mayne Pharma Group Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-7%
Over the last year, the Accounts Receivables growth was -32%. The average annual Accounts Receivables growth rates for Mayne Pharma Group Ltd have been -3% over the past three years , -7% over the past five years .